- Home
- COLL vs GSL Comparison
COLL vs GSL Comparison
Compare COLL & GSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COLL | GSL |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2015 | 2006 |
Fundamental Metrics
Financial Performance| Metric | COLL | GSL |
|---|---|---|
| Price | $49.40 | $34.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $47.50 | $39.00 |
| AVG Volume (30 Days) | ★ 531.1K | 447.2K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | ★ 7.46% |
| EPS Growth | N/A | ★ 24.38 |
| EPS | 1.63 | ★ 11.14 |
| Revenue | ★ $757,067,000.00 | $747,044,000.00 |
| Revenue This Year | $26.35 | $6.69 |
| Revenue Next Year | $3.67 | N/A |
| P/E Ratio | $30.08 | ★ $3.01 |
| Revenue Growth | ★ 26.34 | 6.50 |
| 52 Week Low | $23.23 | $17.73 |
| 52 Week High | $49.49 | $37.22 |
Technical Indicators
Market Signals| Indicator | COLL | GSL |
|---|---|---|
| Relative Strength Index (RSI) | 71.50 | 49.08 |
| Support Level | $47.83 | $32.74 |
| Resistance Level | $49.49 | $34.17 |
| Average True Range (ATR) | 1.34 | 0.76 |
| MACD | -0.19 | -0.41 |
| Stochastic Oscillator | 87.20 | 29.46 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.